Selexis SA and Teneobio, Inc. have entered into a second services agreement to expand Teneobio’s oncology pipeline of Human Heavy-Chain Antibodies (UniAbs), a new class of multi-specific biologics. Teneobio will utilize Selexis’ SUREtechnology Platform to develop research Cell banks (RCBs) for three additional preclinical candidates for the potential treatments of B-cell malignancies and prostate cancer. The companies entered their first services agreementin June 2017 to develop RCBs for multi-specific UniAb candidates for multiple myeloma. 
 
The SUREtechnology Platform helps facilitates the rapid, stable, and cost-effective production of virtually any recombinant Protein and provides integration of the biologics development continuum, spanning discovery to commercialization. 
 
“Selexis’ cell line development technology was very effective in the advancement of Teneobio’s initial bispecific therapeutic Lead ,” said Yemi Onakunle, PhD, MBA, Selexis vice president, licensing and business development. “We’re excited to continue our work with the Teneobio team as it seeks to bring a new class of oncology biologics to patients. Our partners choose Selexis because we deliver stable and high-performing manufacturing Cell Lines , while reducing the time, effort and costs associated with their development. The expansion of this relationship with Teneobio is a testament to our expertise and the competitive edge we’re able to deliver to our partners.”
  
“Beyond TNB-383B, our lead anti-BCMAxCD3 bispecific for the treatment of multiple myeloma, Teneobio is rapidly advancing a pipeline of differentiated multispecific candidates in immuno-oncology. The  productivity and effectiveness of our initial work with Selexis made it an easy decision to apply the company’s protein Expression platform to additional Teneobio preclinical candidates,” said Omid Vafa, PhD, MBA, chief business officer at Teneobio, Inc. “We look forward to continuing to work with Selexis as we bring our programs into the clinic.”